Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 4Unknown 2Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 24Thoracic 12Dermatologic 9Breast 8Head & Neck 6Lymphoid 5Genitourinary 5Tumor-Agnostic 4Sarcoma 4Other solid neoplasm 4Gynecologic 4Plasma cell 2Other hematologic neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Neoplasms 4

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × spartalizumab × Tumor-Agnostic × Clear all
NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

University of California, San Diego

Phase 1 Completed
25 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT04669899 2024-04-09

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Jounce Therapeutics, Inc.

Phase 1/2 Completed
190 enrolled
Tumor-Agnostic

Neoplasms

NCT02828098 2024-01-29

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Highlight Therapeutics

Phase 1 Completed
44 enrolled
Tumor-Agnostic

Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
337 enrolled 42 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡